Raymond James Financial
DFTX

Raymond James Financial’s Definium Therapeutics DFTX Stock Holding History

Raymond James Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448K Buy
23,713
+2,592
+12% +$44K ﹤0.01% 4421
2025
Q4 		$283K Buy
21,121
+3,329
+19% +$41.2K ﹤0.01% 4612
2025
Q3 		$210K Buy
17,792
+763
+4% +$7.12K ﹤0.01% 4602
2025
Q2 		$111K Sell
17,029
-1,450
-8% -$9.54K ﹤0.01% 4826
2025
Q1 		$108K Buy
18,479
+2,475
+15% +$17.7K ﹤0.01% 4536
2024
Q4 		$111K Buy
+16,004
New +$110K ﹤0.01% 4512

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raymond James Financial's DFTX Position: Q1 2026 in Review

Raymond James Financial increased its Definium Therapeutics (DFTX) stake by 12% in Q1 2026, buying an estimated $44K and bringing the position to 23,713 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #4421.

Raymond James Financial first reported a position in DFTX in Q4 2024 and has held it in 6 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Raymond James Financial held 23,713 shares of Definium Therapeutics worth $448K as of Q1 2026.
  • Raymond James Financial bought 2,592 Definium Therapeutics shares in Q1 2026, an estimated $44K.
  • Definium Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4421 holding.
  • Raymond James Financial first reported a position in Definium Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.